Purpose of review A number of molecular and genomic biomarkers that possess the ability to guide treatment or 'actionable targets' are being reported in metastatic prostate cancer. In addition, pathways of resistance to existing therapies and novel agents to overcome them are currently under active investigation. The next wave of investigations is focused on personalized therapy of prostate cancer. The focus of this review article is to provide an update on clinical development in advanced prostate cancer and to highlight the ongoing investigations of biomarker discovery, and ways of overcoming therapeutic resistance. The next generation of clinical trials developing novel targets and compounds promises to be in populations enriched with specific marker expression.
INTRODUCTION
With the wide range of palliative therapeutic options [1] [2] [3] [4] [5] [6] [7] [8] [9] , the management of prostate cancer has become extremely complex and no evidence is currently available to guide the selection of therapy. This has created a dire need for biomarkers to improve the efficiency of the therapeutic sequence, without relying solely on subjective clinical judgment. The advances in the field of genomic medicine have translated into the development of techniques for comprehensive molecular profiling of tumor specimens and have enabled the exploration of the genomic signature of advanced and metastatic prostate cancer subtypes. Whole-exome and transcriptome sequencing has led to the recognition of novel potential driver mutations, somatic mutations and copy number alterations [10] . Importantly, some of these DNA alterations are clinically actionable, and potentially targetable and hold promise for the development of personalized therapeutic options. Mutational profiling is also leading to a better understanding of the biological mechanisms of therapeutic resistance. The focus of this review article is to give a summary of the current clinical perspectives on the indications, pros and cons of the currently approved regimens, and to
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Androgen deprivation therapy
Continuous androgen deprivation (CAD) vs. intermittent androgen deprivation (IAD) was studied as a noninferiority trial in intergroup trial INT 0162 (S9346) [11] . Median overall survival (OS) was 5.8 years in the continuous as compared with 5.1 years in the intermittent arm [hazard ratio 1.10, 95% confidence interval (CI) 0.99-1. 23 ]. This trial also studied quality of life parameters at baseline, 3, 9 and 15 months. Only erectile function and mental health showed statistically significant improvements at 3 months with IAD; however, this advantage was lost at later time points. The results of this trial were contrary to common belief that IAD and CAD have similar outcomes. A recent report critiques the clinical relevance of a margin of noninferiority ranging from 7 months to 1.8 years that was considered a statistically acceptable difference between the two arms [12 & ]. Most treating physicians would concur that a difference of greater than 7 months would be clinically significant and cannot be considered a comparable outcome. In summary, none of the randomized trials conducted have revealed that IAD was better than CAD, and the ones that claimed noninferiority accepted fairly large differences in OS outcome that are not clinically acceptable. In fact, OS was worse in the intermittent group, in some trials such as Southwest Oncology Group (SWOG) 9346, with a median OS difference of almost 8 months, favoring continuous therapy as standard ( Table 1 [ [2] [3] [4] [5] ).
Role of early docetaxel
Early docetaxel in metastatic hormone-sensitive prostate cancer has recently emerged as a new standard of care in the patient population with extensive metastatic burden (Table 1) [13 && ]. The Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer (CHAARTED) study randomized 790 patients to androgen deprivation therapy (ADT) with six cycles of docetaxel vs. ADT alone. With a median followup of 29 months, OS was noted to be significantly higher in the chemo-hormonal group with a difference of 14 months in median OS (hazard ratio 0.61, 95% CI 0.47-0.80). Subgroup analysis of 513 patients with extensive or high-volume disease, defined as visceral metastasis and/or four or more areas of bone metastasis, showed that OS was significantly increased in the chemotherapy group (median OS 49 vs. 32 months, hazard ratio 0.60, 95% CI 0.45-0.81). The subgroup analysis of lowvolume disease composed of 277 patients showed no significant OS benefit (hazard ratio 0.60, 95% CI 0.32-1.13, P ¼ 0.11). Similar results have been observed in the Systemic Therapy in Advancing or
KEY POINTS
Combinations and sequences of current multifaceted therapies are under active investigation.
Personalized therapy based on actionable targets expressed is the future of prostate cancer management.
Immune therapy with check point inhibitors, vaccines and T-cell-based regimens holds promise in CRPC.
Neuroendocrine prostate cancer, perhaps the most lethal form of PC, needs to be tackled with dedicated effort. ]. Two thousand nine hundred sixty-two patients with metastatic or high-risk disease were randomized. The initial results demonstrated an improvement in OS in chemo-hormonal arm vs. ADT alone (median OS 77 vs. 67 months, hazard ratio 0.76, 95% CI 0.63-0.91). In a subset analysis of patients with high-risk nonmetastatic disease, OS benefit persisted in the combined docetaxel and ADT arm (median OS 65 vs. 43 months, hazard ratio 0.73, 95% CI 0.59-0.89). A third study done by the French group [Groupe d'É tude des Tumeurs Uro-Génitales: Association Française d'Urologie (GETUG-AFU) 15 trial] [15] with longer median follow-up of 82.9 months failed to show benefit in a similar patient population but predominantly composed of patients with low-volume metastatic disease. Of the 385 patients in the intention to treat population, 212 had died. Median OS was 46.5 months (39.1-60.6) in the ADT arm vs. The role of early chemotherapy in nonmetastatic high-risk prostate cancer receiving definitive ADT and radiation was studied in Radiation Therapy Oncology Group 0521 [16 & ]. Five hundred sixtytwo evaluable patients were randomized to ADT with radiation vs. ADT with radiation followed by docetaxel. With a median follow-up of 5.5 years, a 4-year OS was 89% (95% CI: 84-92%) and 93% (95% CI: 90-96%) in the arms without and with docetaxel chemotherapy (hazard ratio 0.68, CI 0.44-1.03).
ROLE OF EARLY ABIRATERONE/ ENZALUTAMIDE
Enzalutamide, which is a direct androgen receptor (AR) blocker, has been studied in a phase II trial in the setting of hormone-sensitive prostate cancer without ADT [17] . Sixty-seven men with hormone-sensitive disease, either metastatic or showing progression by prostate-specific antigen (PSA) alone, were treated with enzalutamide. Sixty-two out of sixty-seven (93%) had PSA decline. Abiraterone acetate was studied in a phase II trial (SWOG 1014) in metastatic hormone-sensitive patients who had PSA of 4 or greater, after being on ADT for 6-12 months [18] . Five (13%) patients achieved an undetectable PSA of less than 0.2 ng/ml (95% CI 4-27%), and nine (23%) patients had a nadir PSA level between 0.2 and 4 ng/ml. The study did not reach the protocol prespecified response rate, but it showed that few patients with suboptimal response to ADT can potentially respond to abiraterone [18, 19] .
Our group at Karmanos Cancer Institute is currently conducting a phase II randomized multicenter trial to investigate the combination of enzalutamide þ luteinizing hormone-releasing hormone (LHRH) analogue vs. bicalutamide þ LHRH analogue in metastatic hormone-sensitive prostate cancer (NCT02058706). This study has utilized the PSA nadir after 7 months of ADT as the primary endpoint, which serves as a surrogate for OS outcome. A large global phase III trial with similar study design, but utilizing OS as an endpoint, is currently ongoing [20] .
CURRENT MANAGEMENT OF CASTRATE-RESISTANT PROSTATE CANCER
Advances in chemotherapy
Androgen receptor variant 7 (ARV-7), a truncated form of AR, has been postulated to predict the resistance to abiraterone and enzalutamide-based therapies [21 && ]. In a recent study, ARV-7 was analyzed in circulating tumor cells of patients with metastatic castrate-resistant prostate cancer (mCRPC). In this study, detection of ARV-7 was not associated with primary resistance to taxanebased chemotherapy. On the basis of this analysis, ARV-7 may represent a predictive marker for taxane sensitivity [22] .
Cabazitaxel demonstrated OS benefit post docetaxel and now with the use of docetaxel in hormonesensitive metastatic prostate cancer, it will likely emerge as the default front-line chemotherapy in mCRPC. A phase II trial randomized patients to cabazitaxel with or without carboplatin [23] . With a median follow-up of 11.4 months, median progression-free survival (PFS) was 4.4 months in cabazitaxel alone vs. 6.7 months in the combination arm (95% CI 2.8À5.7 vs. 4.4-8.9, P ¼ 0.01).
Overcoming chemotherapy resistance has been an area of active research but with disappointing clinical results. Docetaxel-based combinations have failed to demonstrate an OS benefit [24] . OGX-011, an antisense inhibitor of clusterin, initially demonstrated promising efficacy in combination with docetaxel-based chemotherapy [25] . Phase III trials of docetaxel and cabazitaxel with/without OGX-011 have revealed no benefit in OS. Median OS of 23.4 months was noted in the custirsen arm vs. 22.2 months with docetaxel and similarly lack of pain control or OS benefit in the cabazitaxel study [26] .
Antibody drug conjugates are agents that utilize a combination of antibody connected by a linker to a chemotherapeutic agent, enabling efficient delivery of chemotherapy to cancer cells. A phase II trial of prostate-specific membrane antigen with monomethyl auristatin E showed antitumor activity and PSA reduction in taxane refractory population [27] . However, the toxicity of antigen-dependent cytotoxic chemotherapies, especially neuropathy, hyperglycemia and constipation, and the modest therapeutic activity have represented a challenge for rapid development of this modality in mCRPC.
IMMUNOTHERAPY
Sipuleucel T has demonstrated OS benefit in the patients with minimally symptomatic/asymptomatic patients with mCRPC [3] . The patients with a PSA of 22 ng/ml or less had a prolonged median OS of 41.2 months as compared with 28.3 months in the placebo arm. Sipuleucel T is best applied to patients in the early or the slowly progressive phases of mCRPC. Other vaccine therapies are being investigated in placebo-controlled trials.
Immune checkpoints such as cytotoxic Tlymphocyte-associated protein 4 and programmed cell death 1 (PD-1/PDL-1) have shown modest efficacy in mCRPC [28, 29] .
ProstVac, a novel immunotherapy, is a PSA-targeted poxviral-based vaccine, administered with three costimulatory molecules (known as TRI-COM) to increase PSA-specific immune responses [30] . The primary endpoint of PFS was unchanged in a placebo controlled randomized trial; however, an 8.5-month improvement in median OS (25.1 vs. 16.6 months) and a 44% reduction in the death rate (hazard ratio 0.56, P ¼ 0.0061) were noted [31] . A randomized placebo controlled multicenter phase III trial (PROSPECT) is currently ongoing and will evaluate three arms: ProstVac-VF and adjuvant granulocyte macrophage stimulating factor, ProstVac-VF and placebo and placebo-only (NCT01322490). The primary endpoint of the ongoing study is OS, which is appropriate for an immune therapy but will require prolonged follow up and may be confounded by subsequent treatments.
ADXS-PSA (Advaixis Inc.), an immunotherapy that delivers PSA antigen to the antigen-presenting cells via a live attenuated gram-positive bacterial vector [32] , has commenced clinical trials in combination with a PD-1 inhibitor pembrolizumab (NCT02325557). PDL-1 expression was noted to be upregulated after antiandrogen and inflammatory cytokine treatment [33] . Clinical trials of pembrolizumab in combination with enzalutamide (NCT02312557) and cryosurgery (NCT02489357) are ongoing.
Bispecific antibodies are being investigated as a nontoxic-targeted approach. In a phase I trial with anti-CD3 and anti-Her2 bispecific antibody in mCRPC, significant decrease in PSA and pain score was noted in three of the seven evaluable patients [34] . The regimen had no serious treatment-related adverse events. Phase II evaluation is ongoing in mCRPC; both in the prechemo and postchemo settings, in combination with the PD-1 inhibitor pembrolizumab. Future evaluation of vaccines and T-cell therapies in combination with immune checkpoint inhibitors should be exciting for the potential of inducing durable remissions.
ANDROGEN-TARGETED THERAPY
An attractive option at present is to use abiraterone and enzalutamide sequentially with the hope of delaying chemotherapy in mCRPC. Unfortunately, it appears that these two agents used in immediate sequence provide minimal benefit, with evidence of cross-resistance. Retrospective analysis of patients treated with abiraterone after progression on docetaxel followed by enzalutamide showed modest PFS of 2.7-3.5 months with less than 20% patients attaining more than 30% decline in PSA [35, 36] . Enzalutamide after docetaxel and abiraterone resulted in 40% of the patients with PSA decline [37] . In addition, there is a threat of encountering neuroendocrine prostate cancer at progression. Post docetaxel, the beneficial effects of either abiraterone or enzalutamide are attenuated and with the increasing use of chemotherapy in hormone naive prostate cancer, this is a very likely future scenario in majority of mCRPC patients. This fact underlines the importance of clinical trials of early use of abiraterone and enzalutamide prior to the emergence of castrate resistance.
Treatment strategy for the nonmetastatic disease state remains an unmet need in prostate cancer and to date no systemic agent has shown proven benefit. ARN-509 and ODM-201 are AR inhibitors currently in placebo controlled double blind trials. Both are AR antagonists that claim higher affinity to AR than enzalutamide and lower central nervous system penetration [38, 39] .
The use of enzalutamide and abiraterone combination in mCRPC is of interest. This therapy mimics complete androgen blockade as per the combination of LHRH analogue with bicalutamide. A phase III (ALLIANCE) trial is testing the use of enzalutamide with or without abiraterone in a multicenter study within the cooperative group setting (NCT 01949337).
An AR splice variant (ARV-7) was detected to be a reliable marker in mCRPC to predict for lack of response to abiraterone or enzalutamide [21 && ]. ARV-7 detection in circulating tumor cells from men with mCRPC was noted to be associated with resistance to enzalutamide and abiraterone. The presence or acquisition of the ARV-7 mutation was associated with the resistance. The study was conducted in only 31 patients each treated with abiraterone or enzalutamide and needs validation in a larger cohort. In addition, the reproducibility of the test needs to be determined and multicenter clinical trial testing is required. Currently, galeterone is being compared with enzalutamide in patients expressing ARV-7 in mCRPC (NCT02438007). Similarly, aldo-keto reductase enzyme family has been implicated in enzalutamide resistance [40] . AR escape, with expansion of cancer cells expressing unregulated glucocorticoid receptor [41] , and via the androstenedione pathway, are also some of the mechanisms of resistance to enzalutamide and abiraterone, respectively.
ADVANCES IN RADIATION THERAPY
External beam radiation therapy has been used for decades for treatment of neuropathic compression and for pain palliation in metastatic prostate cancer. Due to the extensive bone involvement in advanced prostate cancer, radiopharmaceuticals such as strontium-89 and sumarium-43 were introduced to rapidly control multiple sites of pain. However, the severe myelosuppressive effects of these agents limited their clinical application. Radium-223 is a therapy that mimics calcium and has selective uptake in the bones. It utilizes a particles to decrease the penetration into the bone marrow and limits the incidence and extent of cytopenias. Alpharadin or radium-223 was evaluated in a placebo controlled phase III trial in docetaxel pretreated or chemotherapy ineligible mCRPC patients [9] . An OS benefit was noted favoring the radium-223 treatment, and minimal incidences of severe neutropenia and thrombocytopenia (grades 3 and 4 incidence of 2 and 6%, respectively) were noted. Combination studies of radium-223 with abiraterone and enzalutamide are completed and results are awaited. A global three-arm randomized trial evaluating radium-223 at higher doses (80 becquerel units/kg as compared with 50 becquerel units/kg) or prolonged administration (12 vs. 6 months) is complete and will shed light on the optimal regimen of alpharadin therapy.
Novel agents with promising efficacy in castrate-resistant prostate cancer
VT-464 is a small molecule cytochrome P450 17alpha-hydroxylase (CYP17) inhibitor that has shown promise in preclinical studies [42] and is currently in clinical trials (NCT 02445976). EPI-506 is another small molecule N-terminal domain AR inhibitor that is being studied in phase I/II clinical trial [43] . ASN-001 (Asana Biosciences) [44] is a CYP17 lyase inhibitor that selectively binds to and inhibits the lyase activity of CYP17A1 in both the testes and adrenal glands and is currently in phase I/II testing. Galeterone (TOK-001) has antitestosterone production and AR blockade properties and is currently being evaluated in a randomized trial comparing it with enzalutamide in ARV-7 positive mCRPC [45] . AZD 3514 is a first-in-class, oral, selective androgen-receptor down-regulator (SARD) that functions as a powerful AR inhibitor with efficacy in enzalutamide-resistant cell lines. Phase I study of 49 patients [46] determined the dose-limiting toxicities of nausea and emesis, and preliminary efficacy with 17% measurable disease responses and 13% PSA response rates. Insulin-like growth factor receptor inhibitors showed initial promise in mCRPC; however, the toxicity of hyperglycemia and modest clinical activity observed to date are the obstacles in further development of these agents. Disappointing clinical activity was seen with the addition of insulin-like growth factor 1 receptor antibody to ADT in the SWOG 0925 trial in hormone-sensitive advanced prostate cancer [47] . The proportion of patients achieving an undetectable PSA (<0.2 ng/ml) at 28 weeks was 40% with the addition of cixutumumab and 32.3% with ADT alone [47] .
Bet or bromodomains have emerged as actionable targets that play an important role in maintaining AR activity. The BET inhibitors display invitro disruption of AR recruitment to target gene loci and inhibit gene transcription downstream of AR, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity [48] . The efficacy of BET bromodomain inhibition in CRPC xenograft mouse models was superior to that seen by AR antagonists such as enzalutamide. The AR can also promote c-myc upregulation that promotes tumor growth independent of the ligand, and this can also be impacted by BET inhibition [49] .
Selective inhibitors of nuclear exporter (SINE) is a novel class of agents with a distinct and unique mechanism of action. The target, exportin-1 (XPO1), is responsible for export of about 220 proteins including several tumor suppressor and growth regulatory proteins [50] . Many solid tumor malignancies have elevated XPO1 levels and inhibiting this exporter protein has shown inhibition of tumor growth. KPT-330 or selinexor (Karyopharm Inc) was selected for clinical trial testing as the most effective and orally bioavailable SINE. The phase I trial reported dose-limiting toxicities of dehydration, anorexia and fatigue, and preliminary efficacy in mCRPC. All five patients with prostate cancer demonstrated stable disease despite being pretreated with multiple lines of chemotherapy and hormone therapies. The observation of clinical results in the phase I trial led to a phase II trial of KPT-330 in mCRPC which is ongoing [50] .
BIOMARKER-BASED PERSONALIZED THERAPIES IN CASTRATE-RESISTANT PROSTATE CANCER
Therapies investigating molecular pathways that are linked to the AR pathway, or independent of it, are currently in clinical trials and are summarized in Table 2 .
Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors initially were reported to show activity in breast cancer gene (BRCA) mutation carriers with mCRPC [51] . However, recent studies have noted that DNA repair aberrations, with or without BRCA mutations, are susceptible to platinum and PARP inhibitors [52] . A phase II clinical trial of the PARP inhibitor, olaparib, was conducted in mCRPC cases pretreated with at least two prior regimens including chemotherapy [53] . Sixteen of 49 evaluable patients had abnormality in DNA repair gene (most commonly BRCA) detected by next-generation sequencing. Fourteen of these 16 patients (88%) showed response to olaparib compared with only two of 33 (6%) biomarkernegative patients. Radiologic PFS was 9.8 months in the biomarker-positive group compared with 2.7 months in the biomarker-negative group (P < 0.001). Median OS was 13.8 months in the biomarker-positive group and 7.5 months in the biomarker-negative group (P ¼ 0.05).
The loss of phosphatase and tensin homolog in prostate cancer is associated with phosphatidylinositol-3 kinase activity and hence clinical evaluation of single-agent inhibitors of this pathway, or in combinations with enzalutamide or SARDs, is ongoing [54, 55] . Mammalian target of rapamycin (mTOR) overexpression is another mechanism of resistance noted to chemotherapy or ADT [56] .
Combinations of mTOR inhibitors and AR-targeted agents are undergoing evaluation. The combination of carboplatin and mTOR inhibitor everolimus was studied. Modest activity was noted, and patients with loss of Akt on archival tumor tissue had an increased likelihood of clinical benefit with the regimen [57] . 
NEUROENDOCRINE PROSTATE CANCER
Neuroendocrine histology in prostate cancer usually marks the development of highly aggressive disease with a dismal prognosis. It expresses neuroendocrine markers such as chromogranin A, synaptophysin and neuron-specific enolase. This disease typically lacks AR expression and has loss of the copy numbers of tumor suppressors RB1 (85-90%) and displays TP53 (50-60%) mutations [58] . Patients usually present with metastatic disease and low PSA levels. These tumors are known to lack ARs. Small cell cancers of prostate are rare (<1% of prostate cancers); however, the development of neuroendocrine disease is noted after treatment with ADT. In a recent review, 101 pathological specimens from men treated with abiraterone or enzalutamide showed classic small cell cancer in 12% [59] .
Median OS was noted to be 6.6 months in this group. The amplification of aurora kinase A as well as N-myc has been demonstrated in these tumors [59] . These tumors demonstrate AR positive and negative cells and also demonstrate TMPRSS2-ERG gene rearrangement. The latter can also be detected in circulating tumor cells [60] . The loss of cyclin D1 seems to be unique to prostate neuroendocrine tumors. The therapeutic implications of this have not been explored at present [61] . Platinum-based chemotherapy is the standard management; however, relapse rates are very high. Aurora kinase inhibitors and other targeted therapies are under active investigation.
CONCLUSION
Multiple therapies with distinct mechanisms of action are now available for the management of mCRPC. Figure 1 summarizes the current and clinical trial-based treatment algorithm for metastatic prostate cancer. As most of these agents were developed in parallel, no comparison trials exist. The cumulative effect of using multiple therapies in sequence is likely to result in attenuated outcomes, and PFS and OS similar to those seen in clinic trials cannot be realistically expected. The early use of docetaxel is expected to have an impact on the efficacy of abiraterone and/or enzalutamide. Improvement in efficiency of this therapy with the use of predictive biomarkers will go a long way toward improving outcomes, reducing costs and decreasing toxicities. Significant strides have been made in this field, resulting in a clinically relevant impact on the morbidity and mortality of advanced prostate cancer.
The last few years have demonstrated a switch from chemotherapy-based regimens to nonchemotherapy options in mCRPC. This has made systemic therapies widely applicable and feasible, as even the elderly, or those with significant comorbidities, can tolerate the treatments. Now the time is ripe to explore narrowing the use of these therapies based on predictive biomarkers exhibited by these cancers that will escalate therapeutic efficiency. Development of predictive biomarkers for each of these therapies and careful selection of an enriched patient population will reduce costs, enhance outcomes and optimize toxicities. With an exponential increase in actionable targets in mCRPC, the personalized medicine dream is on the brink of turning into reality in this disease.
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